We are live on ! Find out more

NTHI

NeOnc Technologies

NTHI

Market cap $97.9M

3.40 USD

+0.10

3.03%

At close Updated Sep 30, 4:00 PM EDT

Pre-market

After hours

3.45

+0.05

1.47%

1 day

3.03%

5 days

0.29%

1 month

-31.17%

3 months

-24.94%

6 months

-51.43%

Year to date

-61.71%

1 year

-62.56%

5 years

-71.92%

10 years

-71.92%

About: NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.

Employees: 5

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

NeOnc's Powerful Brain Cancer Pipeline Advances

DALLAS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is heading toward another potentially important regulatory milestone, with the U.S. Food and Drug Administration scheduled to meet with the company on November 17, 2026, for an in-person End-of-Phase 1 Type B meeting concerning NEO212, its oral perillyl alcohol-temozolomide conjugate being developed for aggressive central nervous system cancers.

NeOnc's Powerful Brain Cancer Pipeline Advances

Powerful NeOnc Brain Cancer Pipeline Advances

NeOnc (NASDAQ: NTHI) is scheduled to meet with the FDA for an in-person End-of-Phase 1 Type B meeting covering its experimental brain-cancer drug NEO212.

Powerful NeOnc Brain Cancer Pipeline Advances

NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212

CALABASAS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on November 17, 2026, for an in-person End-of-Phase 1 Type B meeting concerning NEO212.

NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212

NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst

DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has picked up fresh Wall Street coverage at a pivotal moment for its experimental brain-cancer pipeline.

NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst

NeOnc's Delivery may Finally Change the Equation for Brain Cancer's Next Frontier

DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com)– NeOnc Technologies Holdings (NASDAQ: NTHI) is becoming a prominent player, as brain cancer research is entering an increasingly sophisticated era.

NeOnc's Delivery may Finally Change the Equation for Brain Cancer's Next Frontier

NeOnc Charting New Nasal Route to Treating Brain Cancer

DENVER, Sept. 21, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – NeOnc Technologies Holdings' (NASDAQ: NTHI) NEO100 deserves attention; not just because its Phase 2a study has suddenly solved brain cancer, but because it is testing a different answer to one of the field's oldest problems.

NeOnc Charting New Nasal Route to Treating Brain Cancer

NeOnc Eliminates Major Dilution Risk as Clinical Story Accelerates

DENVER, Sept. 17, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- NeOnc Technologies (NASDAQ: NTHI) just removed a potentially significant overhang from its capital structure, redeeming all 6,000 outstanding shares of Series A Convertible Preferred Stock for $6 million in cash, with zero common shares issued in the process.

NeOnc Eliminates Major Dilution Risk as Clinical Story Accelerates

NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution

CALABASAS, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has redeemed for cash all 6,000 outstanding shares of its Series A Convertible Preferred Stock (the “Series A Preferred Stock”) at their aggregate stated value of $6.0 million.

NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution

NeOnc's $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA

DENVER, Sept. 16, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- NeOnc Technologies Holdings (NASDAQ: NTHI) executives put even more personal capital behind the company, following positive Phase 2a results for its experimental brain-cancer therapy NEO100.

NeOnc's $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA

NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results

CALABASAS, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that Executive Chairman, President and Chief Executive Officer Amir F.

NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results

See News Rankings

Price charts implemented using Lightweight Charts™